Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

NCT ID: NCT00093093

Last Updated: 2012-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-06-30

Study Completion Date

2006-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Compare the efficacy and safety of viramidine 600 mg twice a day (BID) versus ribavirin 1000/1200 mg/day, both drugs administered in combination with pegylated interferon alfa-2a to treatment-naive patients with chronic hepatitis C (CHC)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Viramidine

Intervention Type DRUG

Ribavirin

Intervention Type DRUG

pegylated interferon alfa-2a

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treatment-naive patients with compensated chronic hepatitis C.
* HCV RNA \>2000 copies/mL (780 IU/mL) as determined by NGI SuperQuant serum HCV RNA quantification, with a lower limit of detection of 100 copies/mL (39 IU/mL).

Exclusion Criteria

* Severe neuropsychiatric disorders
* History or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic heart disease, significant or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic disorders including severe retinopathy, or immune mediated disease
* Pregnant or breast-feeding patients
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bausch Health Americas, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ralph T. Doyle

Role: STUDY_DIRECTOR

Bausch Health Americas, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Arizona

Tucson, Arizona, United States

Site Status

UCSF Fresno- Internal Medicine

Fresno, California, United States

Site Status

Keck School of Medicine, University of Southern California

Los Angeles, California, United States

Site Status

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

Orange Coast Medical Group

Newport Beach, California, United States

Site Status

University of California Davis Medical Center

Sacramento, California, United States

Site Status

Research and Education, Inc.

San Diego, California, United States

Site Status

California Pacific Medical Center

San Francisco, California, United States

Site Status

University of California San Francisco

San Francisco, California, United States

Site Status

San Mateo Medical Center

San Mateo, California, United States

Site Status

University of Colorado Health Sciences Center

Denver, Colorado, United States

Site Status

Rocky Mountain Gastroenterology

Lakewood, Colorado, United States

Site Status

University of Connecticut

Farmington, Connecticut, United States

Site Status

Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Walter Reed Army Medical Center

Washington D.C., District of Columbia, United States

Site Status

Bach and Godofsky

Bradenton, Florida, United States

Site Status

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

Site Status

Atlanta Academic Research Group

Atlanta, Georgia, United States

Site Status

Atlanta Gastroenterology Associates

Atlanta, Georgia, United States

Site Status

Northwestern Memorial Hospital

Chicago, Illinois, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

Indiana University School of Medicine

Indianapolis, Indiana, United States

Site Status

University of Louisville

Louisville, Kentucky, United States

Site Status

Louisiana State University Memorial Hospital

New Orleans, Louisiana, United States

Site Status

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Site Status

Johns Hopkins

Baltimore, Maryland, United States

Site Status

Johns Hopkins University Medical Center

Baltimore, Maryland, United States

Site Status

Maryland Digestive Disease Research

Laurel, Maryland, United States

Site Status

Future Care Studies/Northgate Medical

Springfield, Massachusetts, United States

Site Status

University of Massachusetts Memorial Medical Center

Worcester, Massachusetts, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Bradley Freilich, MD

Kansas City, Missouri, United States

Site Status

Saint Louis University School of Medicine

St Louis, Missouri, United States

Site Status

Atlantic Gastroenterology Associates

Egg Harbor, New Jersey, United States

Site Status

Regional Clinical Research, Inc.

Johnson City, New York, United States

Site Status

North Shore University Hospital

Manhasset, New York, United States

Site Status

Cabrini Medical Center

New York, New York, United States

Site Status

SUNY Upstate Medical University

Syracuse, New York, United States

Site Status

Jacobi Medical Center

The Bronx, New York, United States

Site Status

Bronx VA Medical Center

The Bronx, New York, United States

Site Status

University of North Carolina

Chapel Hill, North Carolina, United States

Site Status

Digestive Health Specialists

Winston-Salem, North Carolina, United States

Site Status

Consultants for Clinical Research

Cincinnati, Ohio, United States

Site Status

MetroHealth Medical Center

Cleveland, Ohio, United States

Site Status

Research Solutions (SMO)

Tulsa, Oklahoma, United States

Site Status

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Site Status

Radiant Research - Austin

Austin, Texas, United States

Site Status

University of Texas

Dallas, Texas, United States

Site Status

VA Medical Center

Houston, Texas, United States

Site Status

INOVA Fairfax Hospital

Annadale, Virginia, United States

Site Status

Kaiser Permanente Medical Center

Falls Church, Virginia, United States

Site Status

Hunter Holmes McGuire Medical Center

Richmond, Virginia, United States

Site Status

Northwest Medical Specialties

Tacoma, Washington, United States

Site Status

Hospital Italiano

Buenos Aires, Buenos Aires, Argentina

Site Status

Fundación CIDEA

Buenos Aires, Buenos Aires, Argentina

Site Status

Hospital Británico

Buenos Aires, Buenos Aires, Argentina

Site Status

Hospital Austral

Pilar, Buenos Aires, Argentina

Site Status

Hospital Centenario

Rosario, Santa Fe Province, Argentina

Site Status

Westmead Hospital

Westmead, New South Wales, Australia

Site Status

Royal Adelaide Hospital

Adelaide, South Australia, Australia

Site Status

Royal Melbourne Hospital

Parkville, Victoria, Australia

Site Status

The Alfred Hospital

Prahran, Victoria, Australia

Site Status

Sir Charles Gairdner Hospital

Nedlands, Western Australia, Australia

Site Status

University of Calgary

Calgary, Alberta, Canada

Site Status

University of Alberta

Edmonton, Alberta, Canada

Site Status

University of Manitoba

Winnipeg, Manitoba, Canada

Site Status

Toronto Western Hospital

Toronto, Ontario, Canada

Site Status

CHU Grenoble Hôpital Michallon, Service d'Hépatogastroentérologie

Grenoble, , France

Site Status

Hopital Saint Joseph Service d'Hépato-gastroentérologie

Marseille, , France

Site Status

Hôpital de l'Archet 2 Service d'Hépato-Gastroentérologie

Nice, , France

Site Status

Hôpital Saint Antoine, Service d'Hépato-Gastroentérologie

Paris, , France

Site Status

C.H.U de Nancy - Hôpital de Brabois Adultes Service d'Hépato-gastroentérologie

Vandouevre Les Nancy, , France

Site Status

Rambam Medical Center Liver Unit

Haifa, , Israel

Site Status

Head of Liver Unit, Holy family Hospital

Nazareth, , Israel

Site Status

Tel Aviv Souraski Medical Center, Liver Unit, Department of Gastro-enterology

Tel Aviv, , Israel

Site Status

Malattie Infettive, Azienda Ospedaliera di Busto Arsizio

Busto Arsizio, , Italy

Site Status

Az. Osp. Universitaria Policlinico "Paolo Giaccone"

Palermo, , Italy

Site Status

IRCCS Policlinico San Matteo

Pavia, , Italy

Site Status

Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS

Rome, , Italy

Site Status

Divisione di Gastroenterologia, Azienda Ospedaliera S.Giovanni Battista

Torino, , Italy

Site Status

Wojewodzki Szpital Obserwacyjno-Zakazny im. T. Browicza

Bydgoszcz, , Poland

Site Status

Szpital Specjalistyczny

Chorzów, , Poland

Site Status

Katedra Chorob Zakaznych i Hepatologii Collegium Medicum Uniwersytetu Jagiellonskiego

Krakow, , Poland

Site Status

Katedra i Klinika Chorob Zakaznych Pomorskiej Akademii Medycznej

Szczecin, , Poland

Site Status

Klinika Chorob Wewnetrznych i Reumatologii CSK MON WIM

Warsaw, , Poland

Site Status

Wojewodzki Szpital Zakazny

Warsaw, , Poland

Site Status

Fundacion de Investigacion de Diego

Santurce, , Puerto Rico

Site Status

Russian State Medical University

Moscow, , Russia

Site Status

City Hospital of Infectious Diseases #10

Saint Petersburg, , Russia

Site Status

Department of gastroenterology, Russian Military Academy; Regional Military Clinical Hospital №442

Saint Petersburg, , Russia

Site Status

City Hospital of Infectious Diseases #30

Saint Petersburg, , Russia

Site Status

Department of infectious diseases, Russian Military Academy

Saint Petersburg, , Russia

Site Status

Smolensk Medical Academy

Smolensk, , Russia

Site Status

Hospital Universitario Germans Trias i Pujol

Badalona, , Spain

Site Status

Hospital Santa Creu I Sant Pau

Barcelona, , Spain

Site Status

Hospital Universitario La Princesa

Madrid, , Spain

Site Status

Hospital Carlos III

Madrid, , Spain

Site Status

Hospital General Universitario de Valencia

Valencia, , Spain

Site Status

Liver and Hepatobiliary Unit, Queen Elizabeth Hospital

Birmingham, , United Kingdom

Site Status

Liver Unit, Royal Infirmary of Edinburgh

Edinburgh, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Canada France Israel Italy Poland Puerto Rico Russia Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RNA003142-302

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.